Abstract Body: Background: Kir2.1 channels maintain the cardiac resting membrane potential and assist in phase 3 repolarization. PKA-mediated phosphorylation modulates Kir2.1 function, impacting heart excitability and rhythm. Using as mass-spetometry based integrated top-down and bottom up proteomic approach, we identified five novel and confirmed a 6^th phosphorylation site. However, which of these residues impact channel function has not been previously identified.
Methods: HEK293 cells were engineered to stably express either WT-Kir2.1. Ablation of the phosphorylation site was achieved with an alanine substitution of the PKA phosphorylation residue (S13A, S14A, S313A,Y326A, T347A, and S425A). Whole-cell patch clamp experiments of WT-Kir2.1 or the phosphorylation mutants were performed using a standard protocol. Following the initial recording, cells were perfused with PKA-stimulating cocktail (20µM Forskolin and 10µ IBMX) for 4 minutes and the protocol was repeated. Clampfit 10.7, GraphPad Prism, and Origin 20 were used for Data Analysis.
Results: HEK293 cells stabling expressing Kir2.1 demonstrate typical inward rectification with a maximum outward current at -50mV and responds to PKA-cocktail with 2.0 pA/pF increase in maximum outward current. Both S13A and S313A had a normal response PKA stimulation. In contrast, ablation of S425 and S14 resulted in no PKA response. T347A showed little response to PKA; however, the current density is very low at baseline, indicating that this residue is necessary for normal Kir2.1 current density. The Y326 is known to be critical for normal protein folding, and ablation of the site resulted in a complete loss of function.
Discussion: Of the 6 PKA sites identified by a proteomic approach, only S425 and S14 functionally influence Kir2.1 response to PKA stimulation. Further molecular dynamics simulation investigation will provide deeper insight into the conformational changes of Kir2.1 in response to phosphorylation at these sites and the relationship of channel phosphorylation with clinical channel mutation residues.